

October 30, 2015  
Symbio Pharmaceuticals Limited  
Fuminori Yoshida  
Representative Director  
President & Chief Executive Officer

## **Completion of Japan Phase 1 Clinical Trial for IV Rigosertib in MDS**

TOKYO, Japan, October 30, 2015 --- Symbio Pharmaceuticals Limited (Headquarters: Tokyo, “Symbio”) announced today the completion of its Japan Phase 1 clinical trial for IV rigosertib (SyB L-1101, IV formulation) in myelodysplastic syndrome (MDS) patients.

Symbio plans to participate in the global Phase 3 trial (“04-30” or “INSPIRE” trial) that Onconova Therapeutics, Inc. (Headquarters: Newtown, PA, “Onconova”) has initiated for IV rigosertib as a treatment for higher-risk MDS after failure of hypomethylating agent (HMA) therapy and plans to initiate the trial for Japanese patients in this year. Marketing approvals in Japan, the US and EU are expected to be received concurrently.

Completion of the Phase 1 trial will not impact the Company’s financial forecast for FY2015.

### **[Contact]**

Investor Relations

Tel: +81 (0)3 5472 1125

### **About Myelodysplastic Syndrome (MDS)**

MDS patients often require frequent blood transfusions due to the development of severe anemia (decrease in number of red blood cells), with a high rate of progression to acute myelogenous leukemia (AML). There are an estimated 11,000 MDS patients in Japan alone, with the number of cases expected to increase as the population ages. MDS and AML are widely recognized as blood disorders that are difficult to manage given the limited therapeutic options available for patients, particularly for patients who have a drug-resistant form of the disease. A high unmet medical need clearly exists for the establishment of new effective therapies to treat both lower- and higher-risk MDS.

### **About Onconova Therapeutics, Inc.**

Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer. Onconova's clinical and pre-clinical stage drug development candidates are derived from its extensive chemical library and are designed to work against specific cellular pathways that are important in cancer cells, while causing minimal damage to normal cells. In addition to rigosertib, Onconova's most advanced drug candidate under development, two other drug

candidates are in clinical trials and several other compounds in the pre-clinical stage of development. For more information, please visit <http://www.onconova.com>.

**About SymBio Pharmaceuticals Limited**

SymBio Pharmaceuticals Ltd. was established in March, 2005, by Fuminori Yoshida who previously served concurrently as Corporate VP of Amgen Inc. and founding President of Amgen Japan. The company's underlying corporate mission is to "deliver hope to patients in need" as it aspires to be a leading specialty pharmaceutical company in Asia Pacific dedicated to addressing underserved medical needs with main therapeutic focus in oncology, hematology and pain management.